The European Commission has authorized Roche's Alecensa as the inaugural and exclusive targeted adjuvant therapy for patients with early-stage ALK-positive lung cancer.
Jun 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Geron Receives FDA Approval for RYTELO™ (imetelstat), a Novel Telomerase Inhibitor, to Treat Transfusion-Dependent Anemia in Adults with Lower-Risk MDS.
Quell Therapeutics progresses QEL-001, their innovative CAR-Treg cell therapy, to the efficacy phase of the LIBERATE Phase 1/2 trial in liver transplant recipients.
Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone.
Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.